Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions

Modern Pathology

Volumn 16, Issue 4, 2003, Pages 299-308

  Parwani, Anil V ^a   Geradts, Joseph ^b   Caspers, Eric ^c   Offerhaus, G Johan ^c   Yeo, Charles J ^a   Cameron, John L ^a   Klimstra, David S ^d   Maitra, Anirban ^a   Hruban, Ralph H ^a   Argani, Pedram ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Carcinoma; Gallbladder; Genetics; Immunohistochemistry; Tumor suppressor gene

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOMA IN SITU; CLINICAL ARTICLE; DYSPLASIA; FEMALE; GALLBLADDER CARCINOMA; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

ADULT; AGED; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; SMAD4 PROTEIN; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0345790165     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000062656.60581.AA     Document Type: Article

References (36)

1. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Atlas of tumor pathology. 3rd series. Fascicle 27. Washington, D.C.: Armed Forces Institute of Pathology; 2000.
2. Levin B. Gallbladder carcinoma. Ann Oncol 1999;10:S129-30.
3. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 1992;70:1493-7.
4. Nugent KP, Spigelman AD, Talbot IC, Phillips RKS. Gallbladder dysplasia in patients with familial adenomatous polyposis. Br J Surg 1994;81:291-2.
5. Chang HJ, Kim SW, Kim Y-T, Kim WH. Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol 1999;12:763-9.
6. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreatic Surg 1999;6:237-44.
7. Wistuba II, Sugio K, Hung J, Kishimto Y, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995;55:2511-5.
8. Wistuba II, Tang M, Maitra A, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61:3795-800.
9. Gorunova L, Parada LA, Limon J, et al. Nonrandom chromosomal aberrations and cytogenetic heterogeneity in gallbladder carcinomas. Genes Chromosomes Cancer 1999;26:312-21.
10. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage 1 gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-8.
11. Wistuba II, Gadzar AF, Roa I, Albores-Saavedra J. p53 protein expression in gallbladder carcinoma and its precursor lesions. An immunohistochemical study. Hum Pathol 1996;27:360-5.
12. Ink4B/MST2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60.
13. Kim Y-T, Kim J, Jang YH, et al. Genetic alterations in gallbladder adenoma, dysplasia, and carcinoma. Cancer Lett 2001;169:59-68.
14. Kim SW, Her K-H, Jang J-Y, Kim W-H, Kim Y-T, Park Y-H. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol 2000;75:246-51.
15. Ajiki T, Fujimori T, Onoyama H, et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426-9.
16. Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T. Point mutation of the K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994;107:1147-53.
17. Imai M, Hoshi T, Ogawa K. K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gel electrophoresis. Cancer 1994;73:2727-33.
18. Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:333-40.
19. Maitra A, Tascilar M, Hruban RH, Offerhaus GJ, Albores-Saavedra J. Small cell carcinoma of the gallbladder. A clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol 2001;25:595-601.
20. Fleming ID, Cooper IS, Henson DE, et al., editors. AJCC cancer staging handbook. Philadelphia, PA: Lippincott-Raven; 1997.
21. Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
22. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43.
23. Geradts J, Kratzke RA, Crush-Stanton S, Wen SF, Lincoln CE. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol 1996;9:339-47.
24. INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene: a comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000;8:71-9.
25. INK4a expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 2001;95:34-8.
26. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998;58:4740-4.
27. Hruban RH, Sturm PDJ, Slebos RJC, et al. Can K-ras mutations be used to distinguish benign bile duct proliferations from metastases to the liver? A molecular analysis of 101 liver lesions from 93 patients. Am J Pathol 1997;151:943-9.
28. Argani P, Shaukat A, Kaushal M, et al. Differing rates of Dpc4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Evidence for a biologic distinction. Cancer 2001;91:1322-41.
29. INK4 protein in gallbladder carcinomas. Clin Cancer Res 2000;6:4096-100.
30. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18:1197-203.
31. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and RB protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996;8:442-5.
32. Ueki K, Ono Y, Henson JW, Efird JY, von Deimling A, Louis D. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-3.
33. Shimizu E, Coxon A, Otterson GA, et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994;9:2441-8.
34. Herrington CS, Graham D, Southern SA, Bramdev A, Chetty R. Loss of retinoblastoma protein expression is frequent in small cell carcinoma of the uterine cervix and is unrelated to HPV type. Hum Pathol 1999;30:906-10.
35. Takubu K, Nakamura K, Sawabe M, et al. Primary small cell undifferentiated carcinoma of the esophagus. Hum Pathol 1999;30:216-21.
36. Wistuba II, Miquel JF, Gadzar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21-5.